Northwestern Mutual Wealth Management Company Has Cut Its Holding in Johnson & Johnson (JNJ) by $19.21 Million as Stock Declined

Johnson & Johnson (NYSE:JNJ) LogoInvestors sentiment decreased to 0.84 in 2019 Q1. Its down 0.02, from 0.86 in 2018Q4. It worsened, as 57 investors sold JNJ shares while 837 reduced holdings. 129 funds opened positions while 620 raised stakes. 1.84 billion shares or 2.89% more from 1.79 billion shares in 2018Q4 were reported. M&T Commercial Bank Corp reported 2.28M shares. Yhb Investment Advsrs has invested 1.81% of its portfolio in Johnson & Johnson (NYSE:JNJ). Pictet Asset Mgmt holds 0.56% or 1.81 million shares in its portfolio. Curbstone Fincl Mgmt holds 1.17% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 30,786 shares. Wallace Cap Management has 2.41% invested in Johnson & Johnson (NYSE:JNJ) for 124,900 shares. Cutter & Co Brokerage Inc holds 0.92% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 23,075 shares. Keybank Natl Association Oh invested in 1.74M shares or 1.45% of the stock. Capital Int Ca reported 0.03% stake. Ledyard National Bank & Trust reported 66,336 shares. Arete Wealth Advisors Ltd Limited Liability Company holds 25,414 shares or 0.74% of its portfolio. 893,391 were reported by Ariel Invs Limited Liability Corporation. Lombard Odier Asset Mgmt (Switzerland) accumulated 0.11% or 7,967 shares. Williams Jones & Assocs Limited Liability Corporation reported 706,656 shares stake. Tci Wealth holds 2.98% or 48,414 shares in its portfolio. Moller Fincl Svcs accumulated 0.47% or 7,525 shares.

Since June 11, 2019, it had 1 insider purchase, and 0 selling transactions for $419,040 activity.

Northwestern Mutual Wealth Management Company decreased its stake in Johnson & Johnson (JNJ) by 30.45% based on its latest 2019Q1 regulatory filing with the SEC. Northwestern Mutual Wealth Management Company sold 138,235 shares as the company’s stock declined 8.26% . The institutional investor held 315,716 shares of the major pharmaceuticals company at the end of 2019Q1, valued at $44.14 million, down from 453,951 at the end of the previous reported quarter. Northwestern Mutual Wealth Management Company who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $344.52B market cap company. The stock increased 0.21% or $0.28 during the last trading session, reaching $130.54. About 6.37 million shares traded. Johnson & Johnson (NYSE:JNJ) has declined 1.48% since August 16, 2018 and is downtrending. It has underperformed by 1.48% the S&P500.

Northwestern Mutual Wealth Management Company, which manages about $22.84B US Long portfolio, upped its stake in Vanguard Bd Index Fd Inc (BSV) by 274,928 shares to 6.00M shares, valued at $477.28M in 2019Q1, according to the filing. It also increased its holding in Vanguard World Fds (VPU) by 42,891 shares in the quarter, for a total of 213,360 shares, and has risen its stake in Churchill Downs Inc (NASDAQ:CHDN).

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on October, 15. They expect $2.00 earnings per share, down 2.44 % or $0.05 from last year’s $2.05 per share. JNJ’s profit will be $5.28 billion for 16.32 P/E if the $2.00 EPS becomes a reality. After $2.58 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -22.48 % negative EPS growth.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Benzinga.com which released: “Social Media Earnings: Facebook And Twitter Prepare To Share – Benzinga” on July 23, 2019, also Seekingalpha.com with their article: “Next courtroom battle for Johnson & Johnson – Seeking Alpha” published on July 21, 2019, Seekingalpha.com published: “Final briefs in Oklahoma opioid lawsuit – Seeking Alpha” on August 01, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Benzinga.com and their article: “Lilly’s Psoriasis Drug Found Superior To J&J’s Tremfya In Phase 4 Study – Benzinga” published on August 13, 2019 as well as Investorplace.com‘s news article titled: “JNJ Stock Is a Way Better Investment Than Bonds or CDs – Investorplace.com” with publication date: August 14, 2019.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 7 analysts covering Johnson \u0026 Johnson (NYSE:JNJ), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Johnson \u0026 Johnson has $157 highest and $140 lowest target. $149.43’s average target is 14.47% above currents $130.54 stock price. Johnson \u0026 Johnson had 14 analyst reports since February 25, 2019 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, February 25 by Citigroup. The firm earned “Outperform” rating on Wednesday, April 17 by Credit Suisse. The firm has “Outperform” rating given on Wednesday, July 17 by Raymond James. The stock of Johnson & Johnson (NYSE:JNJ) earned “Outperform” rating by BMO Capital Markets on Wednesday, April 17. The rating was maintained by Credit Suisse on Thursday, May 16 with “Outperform”. The stock has “Buy” rating by Cowen & Co on Wednesday, March 6. The firm has “Buy” rating by Raymond James given on Monday, March 25. The firm has “Equal-Weight” rating given on Wednesday, April 17 by Morgan Stanley. The rating was initiated by Barclays Capital on Friday, June 21 with “Hold”. Raymond James maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, April 17. Raymond James has “Outperform” rating and $147 target.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.